Saturna Capital CORP Has $30.76 Million Position in Bristol-Myers Squibb Co (NYSE:BMY)

Saturna Capital CORP grew its position in Bristol-Myers Squibb Co (NYSE:BMY) by 0.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 678,264 shares of the biopharmaceutical company’s stock after buying an additional 650 shares during the quarter. Saturna Capital CORP’s holdings in Bristol-Myers Squibb were worth $30,759,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. FMR LLC increased its position in Bristol-Myers Squibb by 313.9% during the 1st quarter. FMR LLC now owns 40,851,887 shares of the biopharmaceutical company’s stock worth $1,949,043,000 after purchasing an additional 30,981,844 shares in the last quarter. Norges Bank acquired a new position in Bristol-Myers Squibb during the 4th quarter worth approximately $797,038,000. Janus Henderson Group PLC increased its position in Bristol-Myers Squibb by 75.7% during the 2nd quarter. Janus Henderson Group PLC now owns 16,156,559 shares of the biopharmaceutical company’s stock worth $732,691,000 after purchasing an additional 6,960,047 shares in the last quarter. Nordea Investment Management AB increased its position in Bristol-Myers Squibb by 380.2% during the 1st quarter. Nordea Investment Management AB now owns 6,252,847 shares of the biopharmaceutical company’s stock worth $298,324,000 after purchasing an additional 4,950,748 shares in the last quarter. Finally, Ronna Sue Cohen increased its position in Bristol-Myers Squibb by 4,702.2% during the 1st quarter. Ronna Sue Cohen now owns 1,518,227 shares of the biopharmaceutical company’s stock worth $1,518,000 after purchasing an additional 1,486,612 shares in the last quarter. Institutional investors own 77.37% of the company’s stock.

Shares of NYSE:BMY traded up $0.13 during trading on Tuesday, reaching $46.64. The stock had a trading volume of 4,605,582 shares, compared to its average volume of 15,124,619. The business’s fifty day moving average is $45.27. The company has a current ratio of 3.88, a quick ratio of 3.75 and a debt-to-equity ratio of 1.51. Bristol-Myers Squibb Co has a 52 week low of $42.48 and a 52 week high of $63.69. The stock has a market capitalization of $77.40 billion, a PE ratio of 11.72, a price-to-earnings-growth ratio of 2.34 and a beta of 0.73.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 25th. The biopharmaceutical company reported $1.18 EPS for the quarter, beating the Zacks’ consensus estimate of $1.06 by $0.12. Bristol-Myers Squibb had a net margin of 26.14% and a return on equity of 47.63%. The company had revenue of $6.27 billion for the quarter, compared to analyst estimates of $6.10 billion. During the same period in the prior year, the firm posted $1.01 EPS. The company’s quarterly revenue was up 10.0% on a year-over-year basis. As a group, research analysts predict that Bristol-Myers Squibb Co will post 4.26 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, August 1st. Stockholders of record on Friday, July 5th were paid a $0.41 dividend. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.52%. The ex-dividend date of this dividend was Wednesday, July 3rd. Bristol-Myers Squibb’s dividend payout ratio is currently 41.21%.

In other news, Director Theodore R. Samuels II acquired 5,000 shares of Bristol-Myers Squibb stock in a transaction dated Thursday, May 16th. The shares were bought at an average cost of $47.29 per share, with a total value of $236,450.00. Following the purchase, the director now owns 27,000 shares in the company, valued at approximately $1,276,830. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Robert J. Bertolini acquired 11,000 shares of Bristol-Myers Squibb stock in a transaction dated Wednesday, July 31st. The stock was purchased at an average cost of $44.72 per share, for a total transaction of $491,920.00. Following the completion of the purchase, the director now owns 11,397 shares in the company, valued at approximately $509,673.84. The disclosure for this purchase can be found here. Corporate insiders own 0.13% of the company’s stock.

A number of equities analysts recently issued reports on BMY shares. JPMorgan Chase & Co. started coverage on shares of Bristol-Myers Squibb in a research report on Friday, May 3rd. They set an “overweight” rating and a $62.00 price objective for the company. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $54.00 price objective for the company in a research report on Tuesday, May 7th. ValuEngine cut shares of Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research report on Tuesday, July 2nd. Argus cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 price objective for the company. in a research report on Monday, May 20th. Finally, Barclays upgraded shares of Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $53.00 to $55.00 in a research report on Friday, May 3rd. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the company. Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus target price of $55.34.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Read More: What is Depreciation?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.